Two type XVII collagen (BP180) mRNA transcripts in human keratinocytes: A long and a short form

Clinical and Experimental Dermatology

Volumn 25, Issue 1, 2000, Pages 71-76

  Molnar, K ^a,b   Van Der Steege, G ^a   Jonkman, M F ^a   Nijenhuis, M ^a   Husz, S ^a   Van Der Meer, J B ^a   Pas, H H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 17; MESSENGER RNA;

3' UNTRANSLATED REGION; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EXON; HUMAN; HUMAN CELL; KERATINOCYTE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; RNA SPLICING; SQUAMOUS CELL CARCINOMA;

AUTOANTIGENS; BASE SEQUENCE; BLOTTING, NORTHERN; CARRIER PROTEINS; CELLS, CULTURED; COLLAGEN; CYTOSKELETAL PROTEINS; HUMANS; KERATINOCYTES; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; RNA PROBES; RNA, MESSENGER; SEQUENCE DELETION;

EID: 0034088926     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2000.00578.x     Document Type: Article

References (25)

1. Labib RS, Anhalt GJ, Patcl H et al Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. / Inummol 1986; 136: 1231-5.
2. Giudice GJ. Emery DJ, Zelickson BD et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. JImmunol 1993; 151: 5742-50.
3. Balding SD, Prost C, Diaz LA et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. / Invest Dermntol 1996; 106: 141-6.
4. Jonkman MF, De Jong MCJM, Heeres K et al. 180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophie benign epidermolysis bullosa. / Clin Invest 1995:95: 1345-52.
5. McGrath JA, Gatalica B, Christiano AM et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophie benign epidermolysis bullosa. Nature Genet 1995; 11: 83-6.
6. Hirako Y, Usukura J, Nishizawa Y, Owaribe K. Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. / Biol Chem 1996; 271: 13739-45.
7. Fairley JA, Heintz PW, Neuburg M, Diaz LA. Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia. Br J Dermatol 1995; 133: 385391.
8. Aho S, Uitto J. 180-kD bullous pemphigoid antigen/type XVII collagen: tissue-specific expression and molecular interactions with keratin 18. / Cell Biochem 1999; 72: 356-67.
9. Yamada T, Endo R, Tsukagoshi K et al. Aberrant expression of a hemidesmosomal protein, bullous pemphigoid antigen 2, in human squamous cell carcinoma. Lab Invest 1996; 75: 589-600.
10. Diaz LA, Ratrie H HI, Saunders WS et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. / Clin Invest 1990; 86: 1088-94.
11. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. / Invest Dermatol 1992; 99: 243-50.
12. Li KH, Sawamura D, Giudice GJ et al. Genomic organization of collagenous domains and chromosomal assignment of human 180-kDa bullous pemphigoid antigen-2, a novel collagen of stratified squamous epithelium. / Biol Chem 1991; 266: 24064-9.
13. Gatalica B, Pulkkinen L, Li K et al. Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophie benign epidermolysis bullosa. Am J Hum Genet 1997: 60: 352-65.
14. Zone JJ, Taylor TB. Kadunce DP, Meyer LJ. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. / Clin Invest 1990; 85: 812-20.
15. Marinkovich MP, Taylor TB, Keene DR et al. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996; 106: 734-8.
16. Pas HH, Kloosterhuis GJ. Heeres K et al. Bullous pemphigoid and linear IgA dermatosis sera recognize a similar 120-kDa keratinocyte collagenous glycoprotein with antigenic crossreactivity to BP180. / Invest Dermatol 1997; 108: 423-9.
17. Zone JJ, Taylor TB, Meyer LJ, Petersen MJ. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. / Invest Dermatol 1998; 110: 207-10.
18. Schacke H, Schumann H, Hammami HN et al. Two forms of collagen XVII in keratinocytes. A full-length transmembrane protein and a soluble ectodomain. / Biol Cliem 1998:273:25937-43.
19. Carey T. Head and neck tumor cell lines. In: Hay RJ, Gazdar A, Park J-G, eds. Atlas of Human Tumor Cell Lines London: Academic Press, Inc., 1994: 79-120.
20. Altschul SF, Madden TL, Schäffer AA et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 1997; 25: 3389-402.
21. Li K. Tamai K, Tan EM, Uitto J. Cloning of type XVII collagen. Complementary and genomic DNA sequences of mouse 180-kilodalton bullous pemphigoid antigen (BPAG2) predict an interrupted collagenous domain, a transmembrane segment, and unusual features in the 5'end of the gene and the 3'-untransIated region of the mRNA. J Biol Cliem 1993; 268: 8825-34.
22. Makalowski VV. Boguski MS. Evolutionary parameters of the transcribed mammalian genome: an analysis of 2,820 orthologous rodent and human sequences. Proc Natl Acad Sä VSA 1998; 95: 9407-12.
23. Decker CJ, Parker R. Diversity of cytoplasmic functions for the 3' untranslated region of eukaryotic transcripts. Curr Opin Cell Biol 1995; 7: 386-92.
24. St Johnston D. The intracellular localization of messenger RNAs. Cell 1995; 81: 161-70.
25. Gray NK, \Vickens M. Control of translation initiation in animals. Amu Rev Cell Dev Biol 1998; 14: 399-458.